Balance Sheet
Cash Flow Statement
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginFCF Payout RatioGross MarginInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Pharma-Bio Serv (PBSV) FCF Margin (2016 - 2026)

Pharma-Bio Serv filings provide 16 years of FCF Margin readings, the most recent being 17.1% for Q1 2026.

  • On a quarterly basis, FCF Margin rose 27.0% to 17.1% in Q1 2026 year-over-year; TTM through Jan 2026 was 2.09%, a 1750.0% increase, with the full-year FY2025 number at 2.46%, up 518.0% from a year prior.
  • FCF Margin hit 17.1% in Q1 2026 for Pharma-Bio Serv, down from 12.99% in the prior quarter.
  • In the past five years, FCF Margin ranged from a high of 30.47% in Q1 2024 to a low of 29.47% in Q2 2024.
  • Median FCF Margin over the past 5 years was 3.37% (2024), compared with a mean of 0.29%.
  • Biggest five-year swings in FCF Margin: crashed -4870bps in 2024 and later soared 3974bps in 2025.
  • Pharma-Bio Serv's FCF Margin stood at 5.35% in 2022, then skyrocketed by 61bps to 8.62% in 2023, then tumbled by -139bps to 3.37% in 2024, then soared by 486bps to 12.99% in 2025, then tumbled by -232bps to 17.1% in 2026.
  • The last three reported values for FCF Margin were 17.1% (Q1 2026), 12.99% (Q4 2025), and 11.94% (Q3 2025) per Business Quant data.